Abstract
Background Perivascular space (PVS) enlargement in ageing and Alzheimer’s disease (AD) and its exacerbators require further investigation.
Methods We studied centrum semiovale (CSO) and basal ganglia (BG) PVS computationally over three to four annual visits in 557 participants of the DZNE multicentre DELCODE cohort. We tested volumetric changes of PVS in relation to ageing, sex, years of education, hypertension, AD diagnosis, and cerebrospinal-fluid-derived Amyloid and Tau positivity and interleukin 6 (IL-6).
Results PVS volumes increased over time. PVS enlargement was associated with baseline white matter hyperintensities. BG-PVS enlargement was related to age and was faster with hypertension. CSO-PVS volumes increased faster with Amyloid and Tau positivity. Higher CSF IL-6 levels predicted PVS volume expansion in both regions and were associated with accelerated PVS enlargement in individuals with Amyloid and Tau positivity.
Conclusion Our work supports the region-specific involvement of white matter hyperintensities, neurotoxic waste accumulation, and inflammation in PVS enlargement.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was supported by the German Centre for Neurodegenerative Diseases (Deutsches Zentrum fuer Neurodegenerative Erkrankungen, DZNE; reference number BN012) and funded by the German Research Foundation (Deutsche Forschungsgemeinschaft, DFG; Project IDs 425899996 and 362321501/RTG 2413 SynAGE). The funding bodies played no role in the design of the study or collection, analysis, or interpretation of data or in writing the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committees of the medical faculties of all participating sites, Berlin (Charite, University Medicine), Bonn, Cologne, Goettingen, Magdeburg, Munich (Ludwig-Maximilians-University), Rostock, and Tuebingen, gave ethical approval for this work. The ethics committee of the medical faculty of the University of Bonn led and coordinated the process.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵Τ Shared first or last authorship
